US FDA approves Scholar Rock's muscle weakness drug
The U.S. Food and Drug Administration on Friday approved Scholar Rock's NASDAQ:SRRK therapy to treat a rare genetic condition that causes muscle weakness.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.